🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Bliss GVS Pharma Limited BLISSGVS NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.blissgvs.com
Company Profile ↓
₹521.10
+241.33% 1Y
Mkt Cap₹5,512.66 Cr
P/E43.42
P/B4.65
Div. Yield0.38%
52W High₹538.55
52W Low₹127.37
Book Value₹112.76
EPS (TTM)₹12.00

Company Overview

Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. The company offers anti-diabetic, anti-infective, anti-inflammatory, antifungal, antihemorrhoidal, antimalarial, antiseptic, cardiovascular, dermatological, gastrointestinal, gynaecology, neoro/cns, ophthalmic, otc drugs, respiratory, urology, and supplementary drug products, as well as engages in pain management services. It exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.4%.

Consistent Profit Growth

Net profit has compounded at 22.1% per year over the last five years.

Healthy Margins

Operating margin of 17.3% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹920.64 Cr (+14.8% YoY); net profit ₹129.13 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +14.8%, earnings +53.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.2%, profit CAGR 22.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:7.19%
1 Year:14.82%

Compounded Profit Growth

5 Years:22.15%
1 Year:53.18%

Stock Price Performance

1 Year:+241.33%
6 Months:+198.51%
3 Months:+101.65%
1 Month:+18.79%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 96% of range
₹127.37 ₹538.55
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)64.96 · Neutral
Price Performance
1M+18.79%
3M+101.65%
6M+198.51%
1Y+241.33%
Valuation vs Sector

P/E of 43.42 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 22.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
43.42
Industry PE
39.97
Forward P/E est.
28.35
PEG Ratio
-
Book Value
₹112.76
Price to Book
4.65
P/S
6.01
EV/EBITDA
34.22
Dividend Yield
0.38%

Growth (CAGR)

Revenue 5Y
7.19%
Profit 5Y
22.15%
Revenue (YoY)
14.82%
Earnings (YoY)
53.18%

Profitability & Returns

ROCE
15.38%
ROE
10.82%
ROA
8.65%
Profit Margin
14.03%
Op Margin
17.28%
Gross Margin
53.83%
EPS (Latest Qtr)
₹3.27
EPS (TTM)
₹12.00

Balance Sheet & Liquidity

Debt/Equity
1.82
Quick Ratio
3.38
Current Ratio
4.02
Debt
₹21.75 Cr
Total Assets
₹1,492.41 Cr
Current Assets
₹946.34 Cr
Working Capital
₹710.79 Cr

Ownership

Promoter Holding
57.51%
Chg in Prom Hold
-0.10%
FII / Inst Holding
6.76%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹5,512.66 Cr
Total Revenue (TTM)
₹920.64 Cr
EBITDA
₹226.78 Cr
Free Cash Flow
₹81.89 Cr
Operating Cash Flow
₹138.72 Cr
Shares Outstanding
₹10.58 Cr
Gross Margin
53.83%
Payout Ratio
8.33%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BLISSGVS Bliss GVS Pharma Limited NSEPHARMA 521.10 43.42 ₹5,512.66 Cr 0.38% 15.38% 10.82% 7.19% 22.15%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 185.00 Cr160.00 Cr212.00 Cr201.00 Cr198.00 Cr184.00 Cr218.00 Cr210.00 Cr197.99 Cr207.47 Cr244.40 Cr218.25 Cr256.99 Cr
Cost of Revenue --------99.43 Cr91.89 Cr118.05 Cr101.66 Cr113.46 Cr
Gross Profit --------98.56 Cr115.58 Cr126.35 Cr116.59 Cr143.54 Cr
Operating Expenses 179.00 Cr135.00 Cr158.00 Cr157.00 Cr170.00 Cr149.00 Cr176.00 Cr181.00 Cr85.51 Cr82.45 Cr102.85 Cr90.15 Cr107.77 Cr
Operating Income 1.00 Cr18.00 Cr48.00 Cr37.00 Cr21.00 Cr27.00 Cr34.00 Cr22.00 Cr13.05 Cr33.13 Cr23.50 Cr26.44 Cr35.77 Cr
EBITDA 6.00 Cr24.00 Cr54.00 Cr44.00 Cr28.00 Cr34.00 Cr41.00 Cr30.00 Cr33.15 Cr76.78 Cr51.94 Cr50.73 Cr55.63 Cr
Interest Expense 5.00 Cr1.00 Cr1.00 Cr2.00 Cr2.00 Cr2.00 Cr4.00 Cr1.00 Cr1.68 Cr5.47 Cr3.04 Cr1.49 Cr2.01 Cr
Pretax Income -1.00 Cr22.00 Cr59.00 Cr40.00 Cr-4.00 Cr30.00 Cr36.00 Cr36.00 Cr23.44 Cr63.11 Cr40.63 Cr40.90 Cr44.95 Cr
Tax Provision 5.61 Cr7.48 Cr15.93 Cr10.80 Cr-96.00 L7.80 Cr10.08 Cr10.44 Cr6.79 Cr18.75 Cr12.04 Cr16.12 Cr7.95 Cr
Net Income 3.00 Cr14.00 Cr43.00 Cr29.00 Cr-5.00 Cr22.00 Cr26.00 Cr26.00 Cr15.54 Cr43.04 Cr27.25 Cr23.27 Cr35.58 Cr
Diluted EPS 0.321.414.052.64-0.871.972.312.261.464.042.542.143.27

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 407.00 Cr547.00 Cr798.00 Cr815.00 Cr899.00 Cr689.00 Cr577.00 Cr-747.43 Cr765.91 Cr801.80 Cr920.64 Cr
Cost of Revenue --------401.32 Cr382.12 Cr413.69 Cr425.06 Cr
Gross Profit --------346.10 Cr383.79 Cr388.11 Cr495.57 Cr
Operating Expenses 304.00 Cr391.00 Cr596.00 Cr618.00 Cr739.00 Cr566.00 Cr471.00 Cr-245.37 Cr249.03 Cr290.35 Cr336.49 Cr
Operating Income 92.00 Cr143.00 Cr183.00 Cr176.00 Cr151.00 Cr110.00 Cr90.00 Cr-100.73 Cr134.76 Cr97.76 Cr159.09 Cr
EBITDA 103.00 Cr156.00 Cr203.00 Cr197.00 Cr160.00 Cr123.00 Cr107.00 Cr-127.99 Cr148.81 Cr161.23 Cr226.78 Cr
Interest Expense 16.00 Cr19.00 Cr20.00 Cr23.00 Cr4.00 Cr8.00 Cr6.00 Cr-3.24 Cr5.56 Cr6.18 Cr3.71 Cr
Pretax Income 96.00 Cr148.00 Cr175.00 Cr145.00 Cr182.00 Cr129.00 Cr104.00 Cr-106.07 Cr116.87 Cr125.64 Cr189.59 Cr
Tax Provision 34.56 Cr47.36 Cr63.00 Cr56.55 Cr54.60 Cr33.54 Cr30.16 Cr-29.34 Cr35.29 Cr35.38 Cr54.86 Cr
Net Income 61.00 Cr100.00 Cr113.00 Cr89.00 Cr127.00 Cr95.00 Cr74.00 Cr-70.86 Cr75.45 Cr84.30 Cr129.13 Cr
Diluted EPS 5.818.007.955.7011.999.436.64-6.727.117.9512.00

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 662.00 Cr762.00 Cr1,023.00 Cr860.00 Cr905.00 Cr1,030.00 Cr1,077.00 Cr-1,156.85 Cr1,211.59 Cr1,301.29 Cr1,492.41 Cr
Current Assets --------697.37 Cr810.87 Cr823.83 Cr946.34 Cr
Cash & Equivalents --------24.96 Cr23.14 Cr23.79 Cr35.14 Cr
Inventory --------103.06 Cr118.45 Cr125.73 Cr150.73 Cr
Receivables --------385.17 Cr404.35 Cr438.80 Cr517.19 Cr
Total Liabilities --------239.43 Cr208.61 Cr209.44 Cr260.65 Cr
Current Liabilities --------193.26 Cr157.41 Cr172.16 Cr235.54 Cr
Long Term Debt --------40.69 Cr35.59 Cr19.85 Cr0
Total Debt 160.00 Cr132.00 Cr225.00 Cr118.00 Cr102.00 Cr126.00 Cr122.00 Cr-101.90 Cr99.84 Cr88.10 Cr21.75 Cr
Total Equity 337.00 Cr412.00 Cr486.00 Cr536.00 Cr646.00 Cr735.00 Cr808.00 Cr-883.90 Cr967.19 Cr1,050.38 Cr1,192.90 Cr
Shares Outstanding --------10.42 Cr10.47 Cr10.54 Cr10.58 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 38.00 Cr113.00 Cr289.00 Cr18.00 Cr40.00 Cr47.00 Cr64.00 Cr135.00 Cr34.31 Cr102.82 Cr105.91 Cr138.72 Cr
Investing Cash Flow -29.00 Cr-50.00 Cr-249.00 Cr48.00 Cr-79.00 Cr-40.00 Cr-45.00 Cr-103.00 Cr-7.75 Cr-83.19 Cr-75.59 Cr-38.28 Cr
Financing Cash Flow -42.00 Cr-40.00 Cr-10.00 Cr-76.00 Cr17.00 Cr-6.00 Cr-21.00 Cr-24.00 Cr-24.94 Cr-20.89 Cr-30.20 Cr-89.21 Cr
Capital Expenditure -33.00 Cr-12.00 Cr-103.00 Cr-25.00 Cr-38.00 Cr-59.00 Cr-9.00 Cr-72.00 Cr-93.80 Cr-28.33 Cr-76.29 Cr-56.83 Cr
Free Cash Flow 5.00 Cr101.00 Cr186.00 Cr-7.00 Cr2.00 Cr-12.00 Cr55.00 Cr63.00 Cr-59.49 Cr74.49 Cr29.63 Cr81.89 Cr
Net Change in Cash -34.00 Cr23.00 Cr30.00 Cr-10.00 Cr-22.00 Cr0-2.00 Cr9.00 Cr1.62 Cr-1.27 Cr12.74 L11.23 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------46.3%50.1%48.4%53.8%
Operating Margin % 22.6%26.1%22.9%21.6%16.8%16.0%15.6%-13.5%17.6%12.2%17.3%
Net Margin % 15.0%18.3%14.2%10.9%14.1%13.8%12.8%-9.5%9.9%10.5%14.0%
ROE % 18.1%24.3%23.3%16.6%19.7%12.9%9.2%-8.0%7.8%8.0%10.8%
ROCE % --------10.5%12.8%8.7%12.7%

Shareholding Pattern

Insiders
57.51%
Institutions
6.76%
Public Float
15.90%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BLISSGVS

Google News Sat, 04 Jul 2026

Is It Smart To Buy Bliss GVS Pharma Limited (NSE:BLISSGVS) Before It Goes Ex-Dividend? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQZEg2bzBqTllZZXpqOFhDLS1tN2ZkY2RSR2RfM1V5NDZxNTBYQXliS3VxSXBreEpQQnFpellCS000X0N6ZXA0SDhuTm55RTdOajlTOHNvaTBjWHVGMkxlaDBqM0ZrSU51ZlBIejBMeDVjNkJjcExPNVA1U29QTGRHbVpMakxiejJiNnlab3…

Google News Mon, 25 May 2026

Bliss GVS hits 20% upper circuit as Anupam Rasayan to acquire up to 43% stake for Rs 1,369 crore - TradingView

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxOWGgxMmxCc1EyMjFKUGNBaWZ4Q2xZbzRCVTlwX2ItS2ptZ1ZnZGxJcmxoMEc5MDBjV01PTjFXS1pHRUpfNkszWUZaZVh1d1JRN2pMTTUwM0xfOTFIVVMtUk0xbFgyWVRNa2FMMWhYRVBfVWZuWGMzNFFhaF9NQnRPMTFtUG14V2ZxUnhWSX…

Google News ue, 06 Jan 2026

Bliss GVS Pharma's (NSE:BLISSGVS) 37% CAGR outpaced the company's earnings growth over the same three-year period - webull.com.my

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE4zY3dWaHZZUFJxQ2FVaTFuVF85OWFkQXZMMEppaGVxRmd0YU9Ld2xSQkg4aldlUHhDZVV6a3U2VENTUTBGT2VoTzJncWNCZnFzeGZzMHlqNHNTLU5fbUx2bVF2Ujctdw?oc=5" target="_blank">Bliss GVS Pharma's (NSE:BLISS…

Google News ue, 26 May 2026

HOT STOCKS: Anupam Rasayan Surges on Bliss GVS Acquisition, PSPPROJECT and JAMNAAUTO Gain, GREENLAM and RAIN Decline, NATIONALUM Near Key SMA Breakout - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxOX3VnLUNSOGdLY1RuQWJDNjhWVHJzUHdKbVdNWE9QY05jVm4yQVVMX1BHOXdCc3BXenh6Ml9CZWxmOEVWcnM3UC1qWjlBNF9fNDU2amoxWGdTU1lhbUJsZkRTMnMxcnJ5cEVDSEJhM294bm9WY0lxY0Jxa3BfaXlVZ2l5dHdzdG9TdTlVWj…

Google News Sat, 30 May 2026

Should You Be Adding Bliss GVS Pharma (NSE:BLISSGVS) To Your Watchlist Today? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQQWE5S3k1dDdMeGN2cW9jbGo4NTZXV1d4R1RKR0xBY01VM2hhcFJ1Q2tRUXNaOXlvZ09sVHhKdlBXbGNmRlhzX1kyUC1NOHZMTUp2U3VtR21aNUU2cDhqMklYbk1Ra1dadXk3Uzg0ZHg4S1JhNDF5MWVhbGdpekVFTGhqVFpfc2xYc2h2Yk…

Google News Wed, 03 Jun 2026

Here's why Bliss GVS Pharma shares have surged over 45% over the last 10 sessions - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPd3N6aTRuczBJYVp5b09HdEZBaTZkZWtqa2tWd3RaWmFuYTlITkpvNTYzTUZCUUx4ckhUdmJtem5icDVDYThFY24wUHk4YW8wSTZsRVM0aU53N2ZUYmpHQ0poSlRkb1M3cDIwck1aNzZRWTRlTGtyaWl1ZlMtTUluLWh4VGFZdHNSOWlwcH…

BLISSGVS — Frequently Asked Questions

What is the current share price of Bliss GVS Pharma Limited (BLISSGVS)?

As of 2026-07-15 09:52 IST, Bliss GVS Pharma Limited (BLISSGVS) trades at ₹521.10 on NSE. Its 52-week range is ₹127.37 to ₹538.55.

What is the market capitalisation of BLISSGVS?

Bliss GVS Pharma Limited (BLISSGVS) has a market capitalisation of ₹5,512.66 Cr on NSE.

What is the P/E ratio of BLISSGVS?

BLISSGVS trades at a trailing price-to-earnings (P/E) ratio of 43.42. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.65.

Does BLISSGVS pay a dividend?

Bliss GVS Pharma Limited (BLISSGVS) currently offers a dividend yield of 0.38%.

What is the return on equity (ROE) of BLISSGVS?

BLISSGVS has a return on equity (ROE) of 10.82%. Its return on capital employed (ROCE) is 15.38%.

Is BLISSGVS a good stock to buy?

This page provides a data-driven analysis of Bliss GVS Pharma Limited (BLISSGVS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space